News coverage about Rockwell Medical (NASDAQ:RMTI) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rockwell Medical earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.3637015760783 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Rockwell Medical (NASDAQ RMTI) traded down $0.01 during midday trading on Friday, hitting $5.86. The stock had a trading volume of 241,590 shares, compared to its average volume of 274,122. The firm has a market capitalization of $303.84, a PE ratio of -13.63 and a beta of 2.02. Rockwell Medical has a twelve month low of $5.06 and a twelve month high of $8.98.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The business had revenue of $14.63 million for the quarter, compared to analysts’ expectations of $13.33 million. Rockwell Medical had a negative return on equity of 46.63% and a negative net margin of 39.28%. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) earnings per share. equities research analysts predict that Rockwell Medical will post -0.44 earnings per share for the current year.
RMTI has been the subject of several research analyst reports. Zacks Investment Research upgraded Rockwell Medical from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research report on Wednesday, October 25th. BidaskClub upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Friday, December 15th.
TRADEMARK VIOLATION NOTICE: “Rockwell Medical (RMTI) Given News Sentiment Score of 0.24” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://transcriptdaily.com/2018/01/13/rockwell-medical-rmti-given-news-sentiment-score-of-0-24.html.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.